Hoffmann-la Roche Inc.

Other

Ludwig-Maximillians-Universität München

Claudio Sustmann

Christian Klein

Wolfgang Schaefer

Ekkehard Moessner

Birgit Bossenmaier

Juergen Michael Schanzer

Pablo Umana

Hubert Kettenberger

Klaus-Peter Kuenkele

Gerhard Niederfellner

Stefan Endres

Manfred Schwaiger

Sebastian Kobold

Guy Georges

Ulrich Brinkmann

Ralf Hosse

Thomas U Hofer

Stefan Dengl

Werner Scheuer

Eike Hoffmann

Lydia Jasmin Hanisch

Rebecca Croasdale

Samuel Moser

Joerg-Thomas Regula

Rebecca Croasdale-Wood

Carole Bourquin

Raffaella Castoldi

Joerg Thomas Regula

Michael Schraeml

Tilman Schlothauer

Sabine Imhof-Jung

Michael Gerg

Jens Fischer

Christian Schantz

Thomas Friess

Sebastian Fenn

Barbara Weiser

Richard John Buick

Adrian Zwick

Martina Geiger

Carmen Peess

Ben-Fillippo Krippendorff

The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Trivalent, bispecific antibodies

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.

Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, &#x3b3;&#x3b4; T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described. The invention also provides the use of said trivalent, bispecific antibody molecules in a method for the treatment of particular diseases as well as a pharmaceutical compositions/medicament comprising said trivalent, bispecific antibody molecules, wherein said trivalent, bispecific antibody molecule(s) is (are) to be administered in combination with transduced T-cells comprising the fusion protein of the invention. The invention also provides a method for the treatment of particular diseases.

Adoptive t-cell therapy

The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.

HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2

The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Nucleic acid encoding dual Fc antigen binding proteins

The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors.host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Monovalent antigen binding proteins

The invention provides anti-TPBG antibodies and methods of using the same.

Anti-TPBG antibodies and methods of use

Dual FC antigen binding proteins

Growing community of inventors

Munich, Germany

Claudio Sustmann